• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Okyo Pharma to present OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a Partner Meeting of ASCRS


(Image Credit: AdobeStock)

(Image Credit: AdobeStock)

Okyo Pharma Ltd announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024, in Boston, Massachusetts.

Gary Jacob, PhD, Okyo’s CEO, will present the data in a company showcase from 1 pm to 2:30 pm Thursday at the Omni Boston Hotel at the Seaport – LevelEnsemble Ballroom C, Breakout 1.

According to the company, OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease.1

‌Moreover, the company noted earlier this year that OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment.

OK-101 recently showed clear statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled trial of OK-101 to treat DED.

According to a news release, Eyecelerator is a partnership between the American Academy of Ophthalmology and ASCRS to accelerate ophthalmic innovation through next-generation business conferences.2

The event is held the Thursday before each partner society's annual meeting, and it spurs innovation by connecting the scientific talent and entrepreneurs advancing eye care with mission-driven investors and business partners who support their success.

Eyecelerator conferences offer a full day of KOL-driven programs highlighting industry advancements, investment trends, and innovative new products disrupting eye care.2

Moreover, according to the news release, the conferences also provide valuable opportunities to network and explore new market potentials and the occasion for dozens of companies to present their novel clinical treatments and emerging technologies that are shaping the future of ophthalmology.

  1. OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease. Press release; January 8, 2024. Accessed January 8, 2024.
  2. OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery. Yahoo Finance. Published April 2, 2024. Accessed April 3, 2024. https://finance.yahoo.com/news/okyo-pharma-announces-upcoming-presentation-110000841.html
Related Videos
Video 3 - "Approaching Asymptomatic Cases with Risk Factors"
Video 2 - "Do Dry Eye Diagnostics Change the Management of Dry Eye?"
Andrew Pucker, OD, PhD
Video 1 - "Challenging the Definition of Dry Eye- Interpreting Diagnostic Tests"
© 2024 MJH Life Sciences

All rights reserved.